IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

BACKGROUND: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. METHODS AND ANALYSIS: Here we present the rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eyerich, Kilian, Weisenseel, Peter, Pinter, Andreas, Schäkel, Knut, Asadullah, Khusru, Wegner, Sven, Muñoz-Elias, Ernesto J, Bartz, Holger, Taut, Friedmann J H, Reich, Kristian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438891/
https://www.ncbi.nlm.nih.gov/pubmed/34518264
http://dx.doi.org/10.1136/bmjopen-2021-049822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438891/
https://www.ncbi.nlm.nih.gov/pubmed/34518264
http://dx.doi.org/10.1136/bmjopen-2021-049822

Ejemplares similares